Evidence map›Paper›PMID 34547056›Full record

ArticlePloS one2021

Cholesterol efflux capacity and its association with prevalent metabolic syndrome in a multi-ethnic population (Dallas Heart Study).

Oludamilola Akinmolayemi, Suzanne Saldanha, Parag H Joshi, Sneha Deodhar, Colby R Ayers, Ian J Neeland, Anand Rohatgi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Oludamilola AkinmolayemiDepartment of Internal Medicine, Columbia University Irving Medical Center and NewYork-Presbyterian Hospital, New York, New York, United States of America.ORCID 0000-0001-9813-9980
Suzanne SaldanhaDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Parag H JoshiDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Sneha DeodharDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Colby R AyersDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Ian J NeelandUniversity Hospitals Harrington Heart and Vascular Institute and Case Western Reserve University School of Medicine, Cleveland, Ohio, United States of America.
Anand RohatgiDivision of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
The University of Texas Southwestern Medical Center · USNewYork–Presbyterian Hospital · USUniversity Hospitals of Cleveland · US

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
The Genetic and Molecular Basis of Cholesterol EffluxR01HL136724 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI ROHATGI, ANAND KUMAR · 2018 to 2022
$3.8M
Molecular Basis of Exercise-induced Changes in HDL FunctionR01HL146462 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI SARZYNSKI, MARK ANDREW · 2019 to 2023
$3.6M
Mentoring Patient-Oriented Research in Deep Lipid Phenotyping for Cardiovascular DiseaseK24HL146838 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI Anand Kumar Rohatgi · 2019 to 2026
$945k
NCATS NIH HHS UL1 TR001105NHLBI NIH HHS K24 HL146838NHLBI NIH HHS R01 HL136724NHLBI NIH HHS R01 HL146462
6 · The paper itself

Abstract

Metabolic syndrome (MetS) is characterized by adiposity and atherogenic dyslipidemia consisting of elevated triglyceride and decreased high density lipoprotein cholesterol (HDL-C) levels however, cholesterol concentration alone does not reflect HDL functionality. Cholesterol efflux capacity (CEC) captures a key anti-atherosclerotic function of HDL; studies linking CEC to MetS have yielded inconsistent findings and lacked racial/ethnic diversity. The aim of this study was to evaluate the association between CEC and MetS in a large multi-ethnic population utilizing two different CEC assays interrogating overlapping but distinct reverse cholesterol transport pathways. A cross-sectional study was performed using the Dallas Heart Study cohort and cholesterol efflux was measured with radiolabeled and fluorescent cholesterol assays. The relationship between CEC and MetS was assessed using multivariable regression analyses. A total of 2241 participants were included (mean age was 50 years; 38% men and 53% Blacks). CEC was independently and inversely associated with MetS irrespective of efflux assay (CEC-radiolabeled, adjusted OR 0·71 [95% CI 0·65-0·80]. CEC-fluorescent, adjusted OR 0·85 [95% CI 0·77-0·94]). Both CEC measures were inversely associated with waist circumference and directly associated with HDL-C but not with other MetS components. There was an interaction by sex but not by race such that the inverse associations between CEC and MetS were somewhat attenuated in men (OR 0·86, 95%CI 0·74-1·01). In this large multi-ethnic cohort, impaired CEC is linked to MetS irrespective of efflux assay and race/ethnicity but less so among men. Future studies are needed to assess whether CEC mediates the atherosclerotic cardiovascular disease risk of MetS.

Indexed as

AdultAtherosclerosisCholesterolCholesterol, HDLCross-Sectional StudiesEthnicityFemaleHumansMaleMetabolic SyndromeMiddle AgedOdds RatioPrevalenceRisk FactorsSex FactorsWaist CircumferenceCholesterolCholesterol, HDL

Identifiers

PMID34547056
PMCPMC8454977
OpenAlexW3199894170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.